Year : 2023 | Volume
: 24 | Issue : 3 | Page : 136--140
Real-world experience in managing atrial fibrillation in patients with renal impairment; Rivaroxaban versus warfarin
Monirah Abdulrahman Albabtain1, Zaid Dakheel Alanazi1, Nawaf Hamoud Al-Mutairi1, Ola Alyafi2, Raneem Albanyan1, Amr A Arafat3
1 Cardiology Clinical Pharmacy Department, Prince Sultan Cardiac Center, Riyadh, Saudi Arabia
2 Department of Clinical Pharmacy, College of Pharmacy, AlMaarefa University, Riyadh, Saudi Arabia
3 Department of Adult Cardiac Surgery, Prince Sultan Cardiac Center, Riyadh, Saudi Arabia; Department of Cardiothoracic Surgery, Tanta University, Tanta, Egypt
Background: The use of rivaroxaban in patients with atrial fibrillation (AF) and chronic kidney disease (CKD) poses the risk of over- or underdosing. We aimed to compare rivaroxaban and warfarin in AF patients with moderate and severe renal impairment.
Methods: This retrospective study was conducted between 2015 and 2016 to compare the use of warfarin (n = 164) and rivaroxaban (n = 149) in patients with AF and moderate or severe CKD. The study outcomes were survival, stroke, and major bleeding events. The median follow-up was 50 months (interquartile range: 23–60).
Results: Thirty-six patients had major bleeding: 24 with rivaroxaban and 12 with warfarin (P = 0.01). The rivaroxaban group had major bleeding in 3 patients with moderate CKD, 4 with severe CKD, and 17 on dialysis. Multivariable analysis of factors affecting major bleeding revealed that warfarin use lowered the risk of bleeding (hazard ratio: 0.34; P = 0.004). Stroke occurred in 14 patients: 6 in the rivaroxaban group and 8 in the warfarin group (P = 0.44). Survival at 1, 3, and 5 years was 89%, 77%, and 71% with warfarin and 99%, 94%, and 88% with rivaroxaban, respectively (P < 0.001). Multivariable analysis showed higher mortality in patients with lower creatinine clearance and those on warfarin.
Conclusions: The safety of warfarin could be better than rivaroxaban in patients with CKD with fewer bleeding complications but similar stroke rates. Further studies on rivaroxaban dosing in patients on dialysis are required.
Ms. Monirah Abdulrahman Albabtain
Prince Sultan Cardiac Center, Riyadh
|How to cite this article:|
Albabtain MA, Alanazi ZD, Al-Mutairi NH, Alyafi O, Albanyan R, Arafat AA. Real-world experience in managing atrial fibrillation in patients with renal impairment; Rivaroxaban versus warfarin.Heart Views 2023;24:136-140
|How to cite this URL:|
Albabtain MA, Alanazi ZD, Al-Mutairi NH, Alyafi O, Albanyan R, Arafat AA. Real-world experience in managing atrial fibrillation in patients with renal impairment; Rivaroxaban versus warfarin. Heart Views [serial online] 2023 [cited 2023 Sep 22 ];24:136-140
Available from: https://www.heartviews.org/article.asp?issn=1995-705X;year=2023;volume=24;issue=3;spage=136;epage=140;aulast=Albabtain;type=0